Cargando…

COVID-19 vaccine hesitancy in Ethiopia in 2021: a multicenter cross-sectional study

INTRODUCTION: Worldwide, hesitancy to be immunized against SARS-CoV-2 is the most common barrier to reducing COVID-19 incidence. Our study investigated determinants for hesitancy and will be helpful to community mobilizers, health professionals and policymakers. OBJECTIVE: To assess the prevalence a...

Descripción completa

Detalles Bibliográficos
Autores principales: Erega, Besfat Berihun, Ferede, Wassie Yazie, Sisay, Fillorenes Ayalew, Tiruneh, Gebrehiwot Ayalew, Ayalew, Abeba Belay, Malka, Erean shigign, Tassew, Habtamu Abie, Alemu, Asrat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729579/
https://www.ncbi.nlm.nih.gov/pubmed/36510492
http://dx.doi.org/10.1016/j.ijregi.2022.11.006
_version_ 1784845499848720384
author Erega, Besfat Berihun
Ferede, Wassie Yazie
Sisay, Fillorenes Ayalew
Tiruneh, Gebrehiwot Ayalew
Ayalew, Abeba Belay
Malka, Erean shigign
Tassew, Habtamu Abie
Alemu, Asrat
author_facet Erega, Besfat Berihun
Ferede, Wassie Yazie
Sisay, Fillorenes Ayalew
Tiruneh, Gebrehiwot Ayalew
Ayalew, Abeba Belay
Malka, Erean shigign
Tassew, Habtamu Abie
Alemu, Asrat
author_sort Erega, Besfat Berihun
collection PubMed
description INTRODUCTION: Worldwide, hesitancy to be immunized against SARS-CoV-2 is the most common barrier to reducing COVID-19 incidence. Our study investigated determinants for hesitancy and will be helpful to community mobilizers, health professionals and policymakers. OBJECTIVE: To assess the prevalence and determinants of hesitancy to COVID-19 vaccination among patients attending public hospitals in South Gondar zone, Ethiopia. METHODS: A multicenter facility-based cross-sectional study was conducted from 1 November to 30 December 2021 to assess the prevalence and determinants of hesitancy to COVID-19 vaccination. Chi-square test and multivariable logistic regression methods were employed using SPSS 23. Significance level was examined using an odds ratio at 95% CI. Multi-collinearity and model fitness were also checked. RESULTS: A total of 415 participants were included in the study, with a questionnaire response rate of 100%. The prevalence of hesitancy to COVID-19 vaccination was 46.02%. Age of >49 years, rural residency, fear of the adverse effects of the vaccines, myths about vaccine ineffectiveness and poor practices in COVID-19 prevention were the most common determinants of hesitancy. CONCLUSIONS: Despite increased global morbidity and mortality due to COVID-19, the prevalence of vaccine hesitancy is still high. Therefore, it is important to create awareness in highly hesitant groups.
format Online
Article
Text
id pubmed-9729579
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-97295792022-12-08 COVID-19 vaccine hesitancy in Ethiopia in 2021: a multicenter cross-sectional study Erega, Besfat Berihun Ferede, Wassie Yazie Sisay, Fillorenes Ayalew Tiruneh, Gebrehiwot Ayalew Ayalew, Abeba Belay Malka, Erean shigign Tassew, Habtamu Abie Alemu, Asrat IJID Reg Coronavirus (COVID-19) Collection INTRODUCTION: Worldwide, hesitancy to be immunized against SARS-CoV-2 is the most common barrier to reducing COVID-19 incidence. Our study investigated determinants for hesitancy and will be helpful to community mobilizers, health professionals and policymakers. OBJECTIVE: To assess the prevalence and determinants of hesitancy to COVID-19 vaccination among patients attending public hospitals in South Gondar zone, Ethiopia. METHODS: A multicenter facility-based cross-sectional study was conducted from 1 November to 30 December 2021 to assess the prevalence and determinants of hesitancy to COVID-19 vaccination. Chi-square test and multivariable logistic regression methods were employed using SPSS 23. Significance level was examined using an odds ratio at 95% CI. Multi-collinearity and model fitness were also checked. RESULTS: A total of 415 participants were included in the study, with a questionnaire response rate of 100%. The prevalence of hesitancy to COVID-19 vaccination was 46.02%. Age of >49 years, rural residency, fear of the adverse effects of the vaccines, myths about vaccine ineffectiveness and poor practices in COVID-19 prevention were the most common determinants of hesitancy. CONCLUSIONS: Despite increased global morbidity and mortality due to COVID-19, the prevalence of vaccine hesitancy is still high. Therefore, it is important to create awareness in highly hesitant groups. Elsevier 2022-12-08 /pmc/articles/PMC9729579/ /pubmed/36510492 http://dx.doi.org/10.1016/j.ijregi.2022.11.006 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Coronavirus (COVID-19) Collection
Erega, Besfat Berihun
Ferede, Wassie Yazie
Sisay, Fillorenes Ayalew
Tiruneh, Gebrehiwot Ayalew
Ayalew, Abeba Belay
Malka, Erean shigign
Tassew, Habtamu Abie
Alemu, Asrat
COVID-19 vaccine hesitancy in Ethiopia in 2021: a multicenter cross-sectional study
title COVID-19 vaccine hesitancy in Ethiopia in 2021: a multicenter cross-sectional study
title_full COVID-19 vaccine hesitancy in Ethiopia in 2021: a multicenter cross-sectional study
title_fullStr COVID-19 vaccine hesitancy in Ethiopia in 2021: a multicenter cross-sectional study
title_full_unstemmed COVID-19 vaccine hesitancy in Ethiopia in 2021: a multicenter cross-sectional study
title_short COVID-19 vaccine hesitancy in Ethiopia in 2021: a multicenter cross-sectional study
title_sort covid-19 vaccine hesitancy in ethiopia in 2021: a multicenter cross-sectional study
topic Coronavirus (COVID-19) Collection
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729579/
https://www.ncbi.nlm.nih.gov/pubmed/36510492
http://dx.doi.org/10.1016/j.ijregi.2022.11.006
work_keys_str_mv AT eregabesfatberihun covid19vaccinehesitancyinethiopiain2021amulticentercrosssectionalstudy
AT feredewassieyazie covid19vaccinehesitancyinethiopiain2021amulticentercrosssectionalstudy
AT sisayfillorenesayalew covid19vaccinehesitancyinethiopiain2021amulticentercrosssectionalstudy
AT tirunehgebrehiwotayalew covid19vaccinehesitancyinethiopiain2021amulticentercrosssectionalstudy
AT ayalewabebabelay covid19vaccinehesitancyinethiopiain2021amulticentercrosssectionalstudy
AT malkaereanshigign covid19vaccinehesitancyinethiopiain2021amulticentercrosssectionalstudy
AT tassewhabtamuabie covid19vaccinehesitancyinethiopiain2021amulticentercrosssectionalstudy
AT alemuasrat covid19vaccinehesitancyinethiopiain2021amulticentercrosssectionalstudy